Today: 29 April 2026
Browse Category

NASDAQ:SRRK 23 August 2025 - 30 December 2025

SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears

SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears

Scholar Rock shares fell 3.2% to $43.76 Tuesday afternoon, underperforming biotech peers as investors watched for updates on FDA reinspection timing for its lead drug, apitegromab. The company aims to resubmit its biologics license application in 2026 after the Indiana fill-finish site, now owned by Novo Nordisk, completes remediation and is reinspected by year-end 2025.
30 December 2025
·
Scholar Rock (NASDAQ: SRRK) Soars on FDA Progress, $200M ATM and Q3 2025 Earnings – November 14, 2025 Update

Scholar Rock (NASDAQ: SRRK) Soars on FDA Progress, $200M ATM and Q3 2025 Earnings – November 14, 2025 Update

Scholar Rock shares surged 26% to $37.98 after an FDA meeting on its SMA therapy and the launch of a $200 million at-the-market stock offering. The company reported a Q3 2025 net loss of $102.2 million, up from $64.5 million a year earlier, with no revenue as it prepares for a potential U.S. launch in 2026. Trading volume topped 2.7 million shares.
14 November 2025
····
Massive Moves: Record Deals, FDA Wins & Crypto Mania Propel Top Stock Gainers (Sep 29, 2025)

Massive Moves: Record Deals, FDA Wins & Crypto Mania Propel Top Stock Gainers (Sep 29, 2025)

Electronic Arts shares jumped 15% after agreeing to a $55 billion buyout led by Saudi Arabia’s PIF, offering $210 per share. Crinetics Pharmaceuticals soared 28% as the FDA approved its oral acromegaly drug. QMMM Holdings surged 19% before the SEC halted trading over suspected manipulation. Scholar Rock gained 12% despite an FDA delay for its spinal atrophy drug.
29 September 2025
·····
Scholar Rock (SRRK) Just Hit a Regulatory Speed Bump—But the Long‑Term Muscle‑Building Story Still Has Legs

Scholar Rock (SRRK) Just Hit a Regulatory Speed Bump—But the Long‑Term Muscle‑Building Story Still Has Legs

The FDA issued a Complete Response Letter for Scholar Rock’s apitegromab on Sept. 23, citing only manufacturing issues at a third-party Indiana plant. Shares fell but analysts, including BMO and Leerink, maintained bullish outlooks, expecting a quick resolution. The EMA review continues, with a possible EU launch in late 2026. Scholar Rock reported $295 million in cash as of June 30.
26 September 2025
··
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

The FDA approved Ionis Pharmaceuticals’ Dawnzera as the first RNA-targeted therapy to prevent hereditary angioedema attacks, priced at about $57,462 per dose. AbbVie’s Rinvoq met key endpoints in a second Phase 3 alopecia areata trial, while Scholar Rock’s apitegromab showed significant motor gains in spinal muscular atrophy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million.
23 August 2025
·······

Stock Market Today

  • Qualcomm Q2 Earnings Preview Amid Smartphone Market Downturn
    April 29, 2026, 1:07 PM EDT. Qualcomm is set to report second-quarter earnings amid a sharp downturn in the global smartphone market. The company, known for its smartphone chips, faces challenges as shipments fell 4.1% in Q1, marking an end to a 10-quarter growth streak. Analyst Ming-Chi Kuo highlights Qualcomm's upcoming AI chip with OpenAI, aiming for mass production in 2028 to challenge Apple and Google's dominance. Despite diversification into data centers and automotive sectors, the handset division, driving most revenue, is expected to drop 12.5% year-over-year. Qualcomm forecasts Q2 revenue of $10.56 billion and earnings per share of $2.55, down from last year. CEO Cristiano Amon's upcoming keynote could shed light on the company's AI and data center strategies amid this challenging market.

Latest article

Silicon Motion Stock Jumps After Q1 Sales Double and AI Storage Outlook Tops Estimates

Silicon Motion Stock Jumps After Q1 Sales Double and AI Storage Outlook Tops Estimates

29 April 2026
Silicon Motion reported first-quarter revenue of $342.1 million, up 105% from a year earlier, and forecast second-quarter sales above Wall Street estimates. Shares rose $45.09 to $194.27 in New York trading. The company cited strong demand for embedded storage controllers and AI-related enterprise storage. CEO Wallace Kou said its MonTitan SSD controller platform will enter volume production this quarter.
Starbucks Stock Surges After Earnings Beat Makes Niccol’s Turnaround Look Real

Starbucks Stock Surges After Earnings Beat Makes Niccol’s Turnaround Look Real

29 April 2026
Starbucks raised its fiscal 2026 outlook after global comparable store sales rose 6.2% in the second quarter, beating analyst estimates. Shares jumped about 10% to $107.03. North American operating margin fell to 9.9% from 11.6% due to higher labor and product costs. The company now expects at least 5% comparable sales growth for the year.
Teradyne Stock Slides After Record AI Quarter. The Guidance Is Why.

Teradyne Stock Slides After Record AI Quarter. The Guidance Is Why.

29 April 2026
Teradyne shares fell 16% to $319.10 Wednesday after the chip-testing company forecast lower second-quarter revenue and profit, despite posting record first-quarter sales of $1.282 billion, up 87% from a year earlier. About 70% of revenue came from AI-related demand, but management warned of “lumpy growth” due to large customer programs.
Go toTop